Log in to save to my catalogue

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with infl...

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with infl...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2035709532

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

About this item

Full title

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

Publisher

England: BMJ Publishing Group LTD

Journal title

Gut, 2019-01, Vol.68 (1), p.25-39

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

ObjectiveVedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn’s disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intestinal T cell trafficking although human data to support this conclusion are scarce. We therefore perform...

Alternative Titles

Full title

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2035709532

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2035709532

Other Identifiers

ISSN

0017-5749

E-ISSN

1468-3288

DOI

10.1136/gutjnl-2018-316023

How to access this item